Fenoldopam: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
ClaireLewis (talk | contribs) |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antihypertensive, Dopamine agonist | *Type: [[Antihypertensive]], Dopamine agonist | ||
*Dosage Forms: 10mg/mL (1 mL), 20mg/2 mL (2 mL) | *Dosage Forms: 10mg/mL (1 mL), 20mg/2 mL (2 mL) | ||
*Routes of Administration: Intravenous | *Routes of Administration: Intravenous | ||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Severe hypertension: Initial 0.01 to 0.3 | *Severe hypertension: Initial 0.01 to 0.3 mcg/kg/minute, increase incrementally 0.05 to 0.1 mcg/kg/minute q 15 minute until target blood pressure is reached (maximum dose recorded in the study was 1.6 mcg/kg/minute), limit for up to 48-hour use. | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 58: | Line 58: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*stimulates dopamine D1-like and | *stimulates dopamine D1-like and α-2 adrenergic receptors | ||
==Comments== | ==Comments== | ||
| Line 68: | Line 68: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Cardiology]] | |||
Latest revision as of 19:47, 22 September 2019
Administration
- Type: Antihypertensive, Dopamine agonist
- Dosage Forms: 10mg/mL (1 mL), 20mg/2 mL (2 mL)
- Routes of Administration: Intravenous
- Common Trade Names: Corlopam
Adult Dosing
- Severe hypertension: Initial 0.01 to 0.3 mcg/kg/minute, increase incrementally 0.05 to 0.1 mcg/kg/minute q 15 minute until target blood pressure is reached (maximum dose recorded in the study was 1.6 mcg/kg/minute), limit for up to 48-hour use.
Pediatric Dosing
- Severe hypertension: Initial 0.2 mcg/kg/minute; increase incrementally 0.3 to 0.5 mcg/kg/minute q 20 to 30 minutes (maximum 0.8 mcg/kg/minute), limit for 4-hour use
Special Populations
- Pregnancy Rating: B
- Lactation risk: Not defined
Renal Dosing
- Adult: Not defined
- Pediatric: Not defined
Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- Caution if:
- sulfite hypersensitivity
- asthma
- glaucoma, intraocular HTN, elevated ICP
- acute stroke
- cardiac disease, arrythmias
- hypokalemia
- active bleeding
- portal hypertension
Adverse Reactions
Serious
- hypotension, severe
- tachycardia
- CHF, MI, angina
- hypokalemia
- leukocytosis
Common
- headache, dizziness
- flushing, diaphoresis, anxiety, tachycardia
- hypotension
- ST-T wave changes
- nausea/vomiting, abdominal pain, diarrhea, constipation
- injection site reaction
- back pain
- nasal congestion
- IOP elevation
Pharmacology
- Half-life: 5 min
- Metabolism: Liver extensively; CYP450
- Excretion: urine 90%, feces 10%
Mechanism of Action
- stimulates dopamine D1-like and α-2 adrenergic receptors